rofecoxib has been researched along with Bladder Cancer in 2 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Two human bladder cancer cell lines were grown in culture using standard techniques and treated with Rofecoxib at doses ranging from 125 microg/well serially diluted down to 8." | 3.72 | COX-2 inhibition demonstrates potent anti-proliferative effects on bladder cancer in vitro. ( Jackson, BJ; Kandzari, S; McFadden, D; Mohseni, H; Riggs, DR; Zaslau, S, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mohseni, H | 1 |
| Zaslau, S | 1 |
| McFadden, D | 1 |
| Riggs, DR | 1 |
| Jackson, BJ | 1 |
| Kandzari, S | 1 |
| Ziegler, J | 1 |
2 other studies available for rofecoxib and Bladder Cancer
| Article | Year |
|---|---|
COX-2 inhibition demonstrates potent anti-proliferative effects on bladder cancer in vitro.
Topics: Apoptosis; Catechin; Cell Division; Cell Line, Tumor; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxyge | 2004 |
Early trials probe COX-2 inhibitors' cancer-fighting potential.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Clinical Trials as Topic; Colonic Neoplasms; Cyc | 1999 |